Impairment of the nerve growth factor pathway driving amyloid accumulation in cholinergic neurons: The incipit of the Alzheimer’s disease story?

Neural Regeneration Research

Volumn 11, Issue 10, 2016, Pages 1553-1556

  Triaca, Viviana ^a   Calissano, Pietro ^a  

^a CNR   (Italy)

Author keywords

Alzheimer s disease onset; Basal forebrain cholinergic neurons; Intraneuronal amyloid generation and release; NGF pathway disturbances

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A; STRESS ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; GENE EXPRESSION; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; POSTSYNAPTIC DENSITY; REVIEW;

EID: 84994884965     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.193224     Document Type: Review

References (14)

1. Baker-Nigh A, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C (2015) Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain 138: 1722-1737.
2. Bayer TA, Wirths O (2010) Intracellular accumulation of amyloid-beta, a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front Aging Neurosci 2: 8.
3. Calissano P, Amadoro G, Matrone C, Ciafre S, Marolda R, Corsetti V, Ciotti MT, Mercanti D, Di Luzio A, Severini C, Provenzano C, Canu N (2010) Does the term ‘trophic’ actually mean anti-amyloidogenic? The case of NGF. Cell Death Differ 17: 1126-1133.
4. Iulita MF, Cuello AC (2014) Nerve growth factor metabolic dysfunction in Alzheimer’s disease and Down syndrome. Trends Pharmacol Sci 35: 338-348.
5. Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, Jiang Y, Nixon RA (2016) Evidence that the rab5 effector APPL1 mediates APP-β CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease. Mol Psychiatry 21: 707-716.
6. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8: 499-509.
7. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163: 83-95.
8. Mesulam M (2004) The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem 11: 43-49.
9. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, Fritz J, Lah J, Ginsberg SD, Wuu J, Scheff SW (2012) Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 71: 1018-1029. .
10. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A (2000) Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 20: 2589-2601.
11. Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A, Rademakers R, Das P, Parisi JE, Graff-Radford NR, Petersen RC, Dickson DW, Bu G (2014) Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease. Brain 137: 1533-1549.
12. Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH (2015) Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72: 1139-1147.
13. Xu W, Weissmiller AM, White JA 2nd, Fang F, Wang X, Wu Y, Pearn ML, Zhao X, Sawa M, Chen S, Gunawardena S, Ding J, Mobley WC, Wu C (2016) Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest 126: 1815-1833.
14. Yang C, Liu Y, Ni X, Li N, Zhang B, Fang X (2014) Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model. Neuropeptides 48: 233-238.